Optogenetic Cancer Therapy Using the Light-Driven Outward Proton Pump Rhodopsin Archaerhodopsin-3 (AR3)
Journal of the American Chemical Society · 2025
DOI: 10.1021/jacs.5c13053 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Chemical Society, 2025. Verfasst von Shin Nakao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8530, Japan. Hauptthemen laut MEDLINE: Optogenetics, Light, Archaeal Proteins, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Takeda Science Foundation, Japan Society for the Promotion of Science, G-7 foundation.
Abstract (Originalsprache)
Medicines used for cancer treatment often cause serious side effects by damaging normal cells due to nonspecific diffusion. To address this issue, we previously developed an optical method to induce apoptotic cell death via intracellular pH alkalinization using the outward proton pump rhodopsin, Archaerhodopsin-3 (AR3) in various noncancer model cells in vitro and in vivo. In this study, we applied this method to cancer cells and tumors to evaluate its potential as an anticancer therapeutic strategy. First, we confirmed that AR3-expressing murine cancer cell lines (MC38, B16F10) showed apoptotic cell death upon green light irradiation, as indicated by increased levels of cell death and apoptosis-related markers. Next, we established stable AR3-expressing MC38 and B16F10 cells by using viral vectors. When these AR3-expressing cells were subcutaneously transplanted into C57BL/6 mice, the resulting tumors initially grew at a rate comparable to that of control tumors lacking AR3 expression or light stimulation. However, upon green light irradiation, AR3-expressing tumors exhibited either a marked reduction in size or significantly suppressed growth, accompanied by the induction of apoptosis signals and decreased proliferation signals. These results demonstrate that AR3-mediated cell death has potent antitumor effects both in vitro and in vivo. This optical method thus holds promise as a novel cancer therapy with potentially reduced side effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8530, Japan.
- Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8530, Japan.
- Department of Neurological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan.
- Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences (Medicine), Okayama University, Okayama 700-8558, Japan.
- Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama 700-8558, Japan.
- Kindai University Faculty of Medicine, Osaka 589-8511, Japan.
ORCID-Profile: Keiichi Kojima, Yuki Sudo
Förderung
- Takeda Science Foundation
- Japan Society for the Promotion of Science
- G-7 foundation
Zitieren
APA
Nakao, S., Kojima, K., Sato, K., Kemmotsu, N., Ohuchi, H., Togashi, Y., & Sudo, Y. (2025). Optogenetic Cancer Therapy Using the Light-Driven Outward Proton Pump Rhodopsin Archaerhodopsin-3 (AR3). Journal of the American Chemical Society. https://doi.org/10.1021/jacs.5c13053
Vancouver
Nakao S, Kojima K, Sato K, Kemmotsu N, Ohuchi H, Togashi Y, et al. Optogenetic Cancer Therapy Using the Light-Driven Outward Proton Pump Rhodopsin Archaerhodopsin-3 (AR3). Journal of the American Chemical Society. 2025. doi:10.1021/jacs.5c13053
BibTeX
@article{Nakao2025,
author = {Nakao, Shin and Kojima, Keiichi and Sato, Keita and Kemmotsu, Naoya and Ohuchi, Hideyo and Togashi, Yosuke and Sudo, Yuki},
title = {Optogenetic Cancer Therapy Using the Light-Driven Outward Proton Pump Rhodopsin Archaerhodopsin-3 (AR3)},
journal = {Journal of the American Chemical Society},
year = {2025},
doi = {10.1021/jacs.5c13053}
}
EUVIMED